Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 14 of 25, showing 5 Applications out of 125 total, starting on record 66, ending on 70

# Protocol No Study Title Investigator(s) & Site(s)

66.

ECCT/20/05/01   ChAdOx1 nCoV-19 trial
    A phase Ib/II single-blinded, randomised, controlled study to determine safety, immunogenicity and efficacy of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 in adults in Kenya   
Principal Investigator(s)
1. George Warimwe
Site(s) in Kenya
KEMRI-CGMRC
 
View

67.

ECCT/20/11/02   IAVI C100
    Safety and Pharmacokinetics of the Combination Broadly Neutralizing  Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and   African Adults (IAVI C100)   
Principal Investigator(s)
1. Nelly Mugo
Site(s) in Kenya
1. Partners in Health Research and Development (PHRD) – CCR-KEMRI (Kiambu county)
2. Kenya AIDS Vaccine Initiative- Institute of Clinical Research (KAVI-ICR) (Nairobi City county)
 
View

68.

ECCT/20/04/01   Solidarity
    An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care   
Principal Investigator(s)
1. Loice Achieng Ombajo
Site(s) in Kenya
1. Kilifi Kemri-Wellcome (Kilifi county)
2. Kenya National Hospital (Nairobi City county)
3. Coast PGH (Mombasa county)
4. The Nairobi Hospital (Nairobi City county)
5. Aga Khan University Hospital (Nairobi City county)
6. Moi Teahing and Referal Hospital (Uasin Gishu county)
7. Kenyatta University teaching research and referal hospital (Kiambu county)
 
View

69.

ECCT/20/03/01   GlycoShig3
    A Phase 2a age descending study to investigate the safety and immunogenicity of the SF2a-TT15 synthetic carbohydrate-based conjugate vaccine against Shigella flexneri 2a in adult, children and infant target population in endemic countries.   
Principal Investigator(s)
1. Fredrick Kipyegon Sawe
Site(s) in Kenya
Kenya Medical Research Institute Walter Reed Project Kericho
 
View

70.

ECCT/19/11/06   Optimize LNG EC
    An Open Label Phase 2 Pharmarcokinetic Study to Evaluate Double - Dose Levonorgestrel Emergency Contraception in Combination withEfavirenz Based Antiretroviral Therapy or Rifampicin Containing Anti - Tuberculosis Therapy. A5375   
Principal Investigator(s)
1. Lucy Chepkurui Koech
Site(s) in Kenya
KEMRI/WRP Kericho
 
View